Comparative Pharmacology
Head-to-head clinical analysis: LURASIDONE HYDROCHLORIDE versus TOVALT ODT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LURASIDONE HYDROCHLORIDE versus TOVALT ODT.
LURASIDONE HYDROCHLORIDE vs TOVALT ODT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lurasidone is an atypical antipsychotic that acts as a full antagonist at D2 and 5-HT2A receptors, with high affinity for 5-HT7 and 5-HT1A receptors, moderate affinity for alpha2C and alpha2A adrenergic receptors, and no appreciable affinity for H1, M1, or alpha1 receptors.
Tovalt ODT (selegiline) is a selective, irreversible inhibitor of monoamine oxidase type B (MAO-B). At therapeutic doses, it inhibits MAO-B more selectively than MAO-A, leading to increased levels of dopamine in the brain.
40 mg orally once daily initially, titrated to 80 mg once daily; maximum 80 mg per day.
20 mg sublingually as needed for BTP, with a minimum interval of 2 hours between doses; maximum 4 doses per day.
None Documented
None Documented
Terminal elimination half-life is approximately 18 hours (range 14–24 hours), supporting once-daily dosing.
Terminal elimination half-life approximately 40–60 hours after multiple dosing; clinical context: reaches steady-state after 2–3 weeks.
Approximately 80% of total radioactivity recovered in feces (67% as metabolites, 9% as unchanged drug) and 19% in urine (mostly metabolites); less than 1% excreted as unchanged parent in urine.
Primarily hepatic metabolism; 70–80% as inactive metabolites in urine, <5% unchanged in urine, 20–30% fecal.
Category A/B
Category C
Atypical Antipsychotic
Atypical Antipsychotic